Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Vir Biotechnology (VIR) stock is back in focus after the company reported a first quarter 2026 net loss, alongside a multibillion-dollar collaboration with Astellas around prostate cancer candidate VIR-5500.
See our latest analysis for Vir Biotechnology.
The share price reaction has been volatile, with a 9.9% one day decline and 9.3% 7 day share price pullback following the earnings loss and Astellas deal. However, the 90 day share price return of 28.9% and 1 year total shareholder return of 71.4% suggest momentum has recently been building from a low base, despite weaker multi year total shareholder returns.
If Vir’s recent swing has you thinking about where else growth stories may emerge in biotech, it could be a good time to scan for other healthcare focused AI plays using the 35 healthcare AI stocks
With Vir posting a US$125.7 million quarterly loss, yet securing a US$1.7b Astellas collaboration and trading well below average analyst price targets, is the stock offering overlooked upside or is the market already pricing in future growth?
Most Popular Narrative: 55.4% Undervalued
Vir Biotechnology’s most followed narrative pegs fair value at $20.78 per share compared to a last close of $9.27, putting a bold gap between model and market.
The strong foundational patent rights to the PRO-XTEN platform enable expansion into additional high value oncology indications, potentially increasing earnings through diversification and broadening revenue streams. Significant progress has been made in oncology with promising T cell engager therapies for colorectal and prostate cancers, suggesting future revenue increases from novel oncology treatments.
Want to see what kind of revenue curve and margin shift would justify that valuation gap? The narrative leans on aggressive growth, richer profitability and a future earnings multiple usually reserved for market leaders.
Result: Fair Value of $20.78 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, the story can change quickly if key trials disappoint or if legal disputes, such as the Brii Biosciences arbitration, reduce confidence in future cash flows.
Find out about the key risks to this Vir Biotechnology narrative.
Another View: What The P/S Multiple Is Saying
The analyst driven fair value of $20.78 suggests upside, but the current P/S of 22.8x paints a very different picture. That multiple is higher than the US Biotechs industry at 10.9x and far above the fair ratio of 0x, raising real questions about valuation risk if growth or margins disappoint.
